Addressing Barriers to Reducing Prescribing and Implementing Deprescribing of Sedative-Hypnotics in Primary Care.
deprescribing
hypnotics
prescription
primary care
sedatives
Journal
The Annals of pharmacotherapy
ISSN: 1542-6270
Titre abrégé: Ann Pharmacother
Pays: United States
ID NLM: 9203131
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
pubmed:
25
7
2021
medline:
11
3
2022
entrez:
24
7
2021
Statut:
ppublish
Résumé
To describe interventions that target patient, provider, and system barriers to sedative-hypnotic (SH) deprescribing in the community and suggest strategies for healthcare teams. Ovid MEDLINE ALL and EMBASE Classic + EMBASE (March 10, 2021). English-language studies in primary care settings. 20 studies were themed as patient-related and prescriber inertia, physician skills and awareness, and health system constraints. Patient education strategies reduced SH dose for 10% to 62% of participants, leading to discontinuation in 13% to 80% of participants. Policy interventions reduced targeted medication use by 10% to 50%. Patient engagement and empowerment successfully convince patients to deprescribe chronic SHs. Quality improvement strategies should also consider interventions directed at prescribers, including education and training, drug utilization reviews, or computer alerts indicating a potentially inappropriate prescription by medication, age, dose, or disease. Educational interventions were effective when they facilitated patient engagement and provided information on the harms and limited evidence supporting chronic use as well as the effectiveness of alternatives. Decision support tools were less effective than prescriber education with patient engagement, although they can be readily incorporated in the workflow through prescribing software. Several strategies with demonstrated efficacy in reducing SH use in community practice were identified. Education regarding SH risks, how to taper, and potential alternatives are essential details to provide to clinicians, patients, and families. The strategies presented can guide community healthcare teams toward reducing the community burden of SH use.
Identifiants
pubmed: 34301151
doi: 10.1177/10600280211033022
pmc: PMC8899816
doi:
Substances chimiques
Hypnotics and Sedatives
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
463-474Références
Br J Gen Pract. 2016 Aug;66(649):e552-60
pubmed: 27266865
PLoS One. 2013 May 17;8(5):e63773
pubmed: 23691095
Age Ageing. 2015 Mar;44(2):213-8
pubmed: 25324330
CMAJ Open. 2017 Mar 03;5(1):E52-E60
pubmed: 28401119
CMAJ. 2003 Apr 1;168(7):835-9
pubmed: 12668540
J Gen Intern Med. 2009 Aug;24(8):897-903
pubmed: 19475459
JAMA. 2017 May 2;317(17):1785-1795
pubmed: 28464141
Eur Neuropsychopharmacol. 2015 Oct;25(10):1566-77
pubmed: 26256008
CNS Drugs. 2007;21(11):947-55
pubmed: 17927298
Eur J Clin Pharmacol. 2020 Mar;76(3):363-381
pubmed: 31838549
J Am Geriatr Soc. 2006 Jun;54(6):963-8
pubmed: 16776793
Drugs Aging. 2013 Oct;30(10):793-807
pubmed: 23912674
J Hosp Med. 2013 Jan;8(1):1-6
pubmed: 23165956
N Z Med J. 2014 Jun 20;127(1396):67-78
pubmed: 24997465
J Am Geriatr Soc. 2013 Sep;61(9):1508-14
pubmed: 24028356
Arch Intern Med. 2006 May 22;166(10):1098-104
pubmed: 16717172
BMC Res Notes. 2012 Dec 13;5:684
pubmed: 23237104
Can Fam Physician. 2010 Nov;56(11):e398-406
pubmed: 21075981
Br J Gen Pract. 2006 Dec;56(533):964-7
pubmed: 17132386
JAMA Intern Med. 2016 Aug 1;176(8):1223-5
pubmed: 27379377
Br J Psychiatry. 2003 Jun;182:498-504
pubmed: 12777340
J Am Geriatr Soc. 2015 Nov;63(11):2227-46
pubmed: 26446832
Prim Care Companion CNS Disord. 2018 May 31;20(3):
pubmed: 29873949
Ther Adv Drug Saf. 2018 Oct 20;9(12):687-698
pubmed: 30546863
Curr Drug Saf. 2006 Jan;1(1):63-71
pubmed: 18690916
Patient Educ Couns. 2013 Jul;92(1):81-7
pubmed: 23541509
Drugs R D. 2017 Dec;17(4):493-507
pubmed: 28865038
Int J Drug Policy. 2017 Jan;39:138-139
pubmed: 27856134
JAMA Intern Med. 2019 Jul 1;179(7):965-972
pubmed: 31157831
J Am Med Dir Assoc. 2018 Apr;19(4):371.e11-371.e17
pubmed: 29402652
BMJ Open. 2014 Dec 08;4(12):e006544
pubmed: 25488097
JAMA. 2018 Nov 13;320(18):1889-1898
pubmed: 30422193
J Gen Intern Med. 2007 Sep;22(9):1335-50
pubmed: 17619935
Swiss Med Wkly. 2013 Jan 17;143:w13745
pubmed: 23348819
Int J Geriatr Psychiatry. 2013 Mar;28(3):248-55
pubmed: 22565497
Curr Sleep Med Rep. 2017;3(2):48-56
pubmed: 28553574
Ann Intern Med. 2016 Jul 19;165(2):125-33
pubmed: 27136449
Br J Gen Pract. 2016 Feb;66(643):e85-91
pubmed: 26823269
JAMA Intern Med. 2014 Jun;174(6):890-8
pubmed: 24733354
Am J Public Health. 2011 Aug;101(8):1429-33
pubmed: 21680913
Sleep. 2014 Feb 01;37(2):343-9
pubmed: 24497662
Fam Pract. 2011 Jun;28(3):253-9
pubmed: 21193495
BMJ. 2016 Feb 02;352:i90
pubmed: 26837813
Pharm World Sci. 2002 Dec;24(6):231-5
pubmed: 12512155
Drug Alcohol Depend. 2005 Apr 4;78(1):49-56
pubmed: 15769557
Fam Pract. 2010 Jun;27(3):320-7
pubmed: 20237108
Australas Psychiatry. 2009 Aug;17(4):300-5
pubmed: 19585293
NCHS Data Brief. 2013 Aug;(127):1-8
pubmed: 24152538
Aust Fam Physician. 2000 Nov;29(11):1104-7
pubmed: 11127075
CMAJ. 2003 Nov 11;169(10):1015-20
pubmed: 14609970
Br J Psychiatry. 2014 Jun;204(6):471-9
pubmed: 24526745
Br J Gen Pract. 2016 Jun;66(647):e410-5
pubmed: 27114208
Ann Intern Med. 2015 Aug 4;163(3):191-204
pubmed: 26054060
J Clin Sleep Med. 2017 Feb 15;13(2):307-349
pubmed: 27998379